Are we close to a prognostic index for cutaneous T cell lymphoma?

Leukemia and Lymphoma

Volumn 55, Issue 1, 2014, Pages 7-8

  Prince, H Miles ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; BIOLOGICAL MARKER; HISTONE DEACETYLASE INHIBITOR;

CANCER PROGNOSIS; CUTANEOUS T CELL LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LARGE CELL LYMPHOMA; MYELODYSPLASTIC SYNDROME; NOTE; PRIORITY JOURNAL; SCORING SYSTEM; TOTAL SKIN ELECTRON THERAPY;

HUMANS; MYCOSIS FUNGOIDES; SKIN NEOPLASMS;

EID: 84891365117     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.809081     Document Type: Note

References (15)

1. Bunn PA Jr, Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 1979; 63: 725-728.
2. Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-Term outcome of 525 patients with mycosis fungoides and Sezary syndrome: Clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139: 857-866.
3. Vonderheid EC, Pavlov I, Delgado JC, et al. Prognostic factors and risk stratification in early mycosis fungoides. Leuk Lymphoma 2014; 55; 44-50.
4. Van Doorn R, Van Haselen CW, Van Voorst Vader PC, et al. Mycosis fungoides: Disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000; 136: 504-510.
5. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: Validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J. Clin Oncol 2010; 28: 4730-4739.
6. Diamandidou E, Colome M, Fayad L, et al. Prognostic factor analysis in mycosis fungoides/Sezary syndrome. J. Am Acad Dermatol 1999; 40: 914-924.
7. Suzuki SY, Ito K, Ito M, et al. Prognosis of 100 Japanese patients with mycosis fungoides and Sezary syndrome. J. Dermatol Sci 2010; 57: 37-43.
8. Talpur R, Singh L, Daulat S, et al. Long-Term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clin Cancer Res 2012; 18: 5051-5060.
9. Marti RM, Estrach T, Reverter JC, et al. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 1991; 127: 1511-1516.
10. Hoppe RT, Medeiros LJ, Warnke RA, et al. CD8-positive tumorinfi ltrating lymphocytes influence the long-Term survival of patients with mycosis fungoides. J. Am Acad Dermatol 1995; 32: 448-453.
11. Vermeer MH, Van Doorn R, Dukers D, et al. CD8-T cells in cutaneous T-cell lymphoma: Expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior. J. Clin Oncol 2001; 19: 4322-4329.
12. Edinger JT, Clark BZ, Pucevich BE, et al. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J. Surg Pathol 2009; 33: 1860-1868.
13. Abeni D, Frontani M, Sampogna F, et al. Circulating CD8-lymphocytes, white blood cells, and survival in patients with mycosis fungoides. Br J. Dermatol 2005; 153: 324-330.
14. Tancrede-Bohin E, Ionescu MA, de La Salmoniere P, et al. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. Arch Dermatol 2004; 140: 1057-1061.
15. Green SB, Byar DP, Lamberg S I. Prognostic variables in mycosis fungoides. Cancer 1981; 47: 2671-2677.